Abstract
Summary
Nonalcoholic steatohepatitis is a syndrome causes liver damage develops in the individuals who are not alcoholic. The primary mechanisms of nonalcoholic steatohepatitis are obesity, glucose intolerance, metabolic stress, inflammation, dyslipidemia and fibrosis. Nonalcoholic steatohepatitis can develop into cirrhosis and liver cancer. For the diagnosis of the nonalcoholic steatohepatitis, liver biopsy, imaging procedures and various types of blood tests including complete blood count, fasting blood sugar, liver enzyme tests etc. are required. The common nonalcoholic steatohepatitis treatment may include weight loss, type-2 diabetes treatment, a decrease of obesity etc. However, many drugs have been tested for the nonalcoholic steatohepatitis treatment only a few drugs such as vitamin E and pioglitazone showed a positive effect. Other drugs such as ursodeoxycholic acid, metformin, statins, orlistat and pentoxifylline showed only partially positive results.The major elements that can be considered for the pathological protagonists of nonalcoholic steatohepatitis are oxidative stress, altered lipid metabolism adipose and pancreas tissues, bile acids, gut microbiota, bacterial endotoxins, and systemic chronic inflammation.
The global market for Nonalcoholic Steatohepatitis Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nonalcoholic Steatohepatitis Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Nonalcoholic Steatohepatitis Treatment by region & country, by Type, and by Application.
The Nonalcoholic Steatohepatitis Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nonalcoholic Steatohepatitis Treatment.
Market Segmentation
By Company
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Segment by Type:
Solid
Liquid
Segment by Application
Hospital
Diagnostic Center
Specialized Clinic
Hospital Pharmacy
Drug Store
Mail Order Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Nonalcoholic Steatohepatitis Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Nonalcoholic Steatohepatitis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Nonalcoholic Steatohepatitis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Nonalcoholic Steatohepatitis Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nonalcoholic Steatohepatitis Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Nonalcoholic Steatohepatitis Treatment by region & country, by Type, and by Application.
The Nonalcoholic Steatohepatitis Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nonalcoholic Steatohepatitis Treatment.
Market Segmentation
By Company
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Segment by Type:
Solid
Liquid
Segment by Application
Hospital
Diagnostic Center
Specialized Clinic
Hospital Pharmacy
Drug Store
Mail Order Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Nonalcoholic Steatohepatitis Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Nonalcoholic Steatohepatitis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Nonalcoholic Steatohepatitis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Nonalcoholic Steatohepatitis Treatment Product Introduction
1.2 Global Nonalcoholic Steatohepatitis Treatment Market Size Forecast
1.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value (2019-2030)
1.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Volume (2019-2030)
1.2.3 Global Nonalcoholic Steatohepatitis Treatment Sales Price (2019-2030)
1.3 Nonalcoholic Steatohepatitis Treatment Market Trends & Drivers
1.3.1 Nonalcoholic Steatohepatitis Treatment Industry Trends
1.3.2 Nonalcoholic Steatohepatitis Treatment Market Drivers & Opportunity
1.3.3 Nonalcoholic Steatohepatitis Treatment Market Challenges
1.3.4 Nonalcoholic Steatohepatitis Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Nonalcoholic Steatohepatitis Treatment Players Revenue Ranking (2023)
2.2 Global Nonalcoholic Steatohepatitis Treatment Revenue by Company (2019-2024)
2.3 Global Nonalcoholic Steatohepatitis Treatment Players Sales Volume Ranking (2023)
2.4 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Company Players (2019-2024)
2.5 Global Nonalcoholic Steatohepatitis Treatment Average Price by Company (2019-2024)
2.6 Key Manufacturers Nonalcoholic Steatohepatitis Treatment Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Nonalcoholic Steatohepatitis Treatment Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Nonalcoholic Steatohepatitis Treatment
2.9 Nonalcoholic Steatohepatitis Treatment Market Competitive Analysis
2.9.1 Nonalcoholic Steatohepatitis Treatment Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Nonalcoholic Steatohepatitis Treatment Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis Treatment as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Solid
3.1.2 Liquid
3.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type
3.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Nonalcoholic Steatohepatitis Treatment Sales Value, by Type (%) (2019-2030)
3.3 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Type
3.3.1 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Nonalcoholic Steatohepatitis Treatment Sales Volume, by Type (2019-2030)
3.3.3 Global Nonalcoholic Steatohepatitis Treatment Sales Volume, by Type (%) (2019-2030)
3.4 Global Nonalcoholic Steatohepatitis Treatment Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Diagnostic Center
4.1.3 Specialized Clinic
4.1.4 Hospital Pharmacy
4.1.5 Drug Store
4.1.6 Mail Order Pharmacy
4.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application
4.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Nonalcoholic Steatohepatitis Treatment Sales Value, by Application (%) (2019-2030)
4.3 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Application
4.3.1 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Nonalcoholic Steatohepatitis Treatment Sales Volume, by Application (2019-2030)
4.3.3 Global Nonalcoholic Steatohepatitis Treatment Sales Volume, by Application (%) (2019-2030)
4.4 Global Nonalcoholic Steatohepatitis Treatment Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region
5.1.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (2019-2024)
5.1.3 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (2025-2030)
5.1.4 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (%), (2019-2030)
5.2 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Region
5.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Region (2019-2024)
5.2.3 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Region (2025-2030)
5.2.4 Global Nonalcoholic Steatohepatitis Treatment Sales Volume by Region (%), (2019-2030)
5.3 Global Nonalcoholic Steatohepatitis Treatment Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
5.4.2 North America Nonalcoholic Steatohepatitis Treatment Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
5.5.2 Europe Nonalcoholic Steatohepatitis Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
5.6.2 Asia Pacific Nonalcoholic Steatohepatitis Treatment Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
5.7.2 South America Nonalcoholic Steatohepatitis Treatment Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
5.8.2 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Nonalcoholic Steatohepatitis Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Nonalcoholic Steatohepatitis Treatment Sales Value
6.2.1 Key Countries/Regions Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
6.2.2 Key Countries/Regions Nonalcoholic Steatohepatitis Treatment Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
6.3.2 United States Nonalcoholic Steatohepatitis Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Nonalcoholic Steatohepatitis Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
6.4.2 Europe Nonalcoholic Steatohepatitis Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Nonalcoholic Steatohepatitis Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
6.5.2 China Nonalcoholic Steatohepatitis Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Nonalcoholic Steatohepatitis Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
6.6.2 Japan Nonalcoholic Steatohepatitis Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Nonalcoholic Steatohepatitis Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
6.7.2 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Nonalcoholic Steatohepatitis Treatment Sales Value, 2019-2030
6.9.2 India Nonalcoholic Steatohepatitis Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Nonalcoholic Steatohepatitis Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Information
7.1.2 AstraZeneca Introduction and Business Overview
7.1.3 AstraZeneca Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.1.4 AstraZeneca Nonalcoholic Steatohepatitis Treatment Product Offerings
7.1.5 AstraZeneca Recent Development
7.2 Arena Pharmaceuticals
7.2.1 Arena Pharmaceuticals Company Information
7.2.2 Arena Pharmaceuticals Introduction and Business Overview
7.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Offerings
7.2.5 Arena Pharmaceuticals Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.3.4 GSK Nonalcoholic Steatohepatitis Treatment Product Offerings
7.3.5 GSK Recent Development
7.4 Novo Nordisk
7.4.1 Novo Nordisk Company Information
7.4.2 Novo Nordisk Introduction and Business Overview
7.4.3 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Product Offerings
7.4.5 Novo Nordisk Recent Development
7.5 Roche
7.5.1 Roche Company Information
7.5.2 Roche Introduction and Business Overview
7.5.3 Roche Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Roche Nonalcoholic Steatohepatitis Treatment Product Offerings
7.5.5 Roche Recent Development
7.6 Vivus
7.6.1 Vivus Company Information
7.6.2 Vivus Introduction and Business Overview
7.6.3 Vivus Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Vivus Nonalcoholic Steatohepatitis Treatment Product Offerings
7.6.5 Vivus Recent Development
7.7 Arisaph Pharmaceuticals
7.7.1 Arisaph Pharmaceuticals Company Information
7.7.2 Arisaph Pharmaceuticals Introduction and Business Overview
7.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Offerings
7.7.5 Arisaph Pharmaceuticals Recent Development
7.8 Cempra Pharmaceuticals
7.8.1 Cempra Pharmaceuticals Company Information
7.8.2 Cempra Pharmaceuticals Introduction and Business Overview
7.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Offerings
7.8.5 Cempra Pharmaceuticals Recent Development
7.9 Galectin Therapeutics
7.9.1 Galectin Therapeutics Company Information
7.9.2 Galectin Therapeutics Introduction and Business Overview
7.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Product Offerings
7.9.5 Galectin Therapeutics Recent Development
7.10 Galmed Pharmaceuticals
7.10.1 Galmed Pharmaceuticals Company Information
7.10.2 Galmed Pharmaceuticals Introduction and Business Overview
7.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Offerings
7.10.5 Galmed Pharmaceuticals Recent Development
7.11 Genfit
7.11.1 Genfit Company Information
7.11.2 Genfit Introduction and Business Overview
7.11.3 Genfit Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Genfit Nonalcoholic Steatohepatitis Treatment Product Offerings
7.11.5 Genfit Recent Development
7.12 Gilead
7.12.1 Gilead Company Information
7.12.2 Gilead Introduction and Business Overview
7.12.3 Gilead Nonalcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Gilead Nonalcoholic Steatohepatitis Treatment Product Offerings
7.12.5 Gilead Recent Development
8 Industry Chain Analysis
8.1 Nonalcoholic Steatohepatitis Treatment Industrial Chain
8.2 Nonalcoholic Steatohepatitis Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Nonalcoholic Steatohepatitis Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Nonalcoholic Steatohepatitis Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer